RxDoctor Payments Data

Verne Webster, MD

Internal Medicine · Madison, ALNPI 1932163920

Payments from drug & device makers

$7,771in general payments, 2019–2025

Across 497 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Novo Nordisk$769
  • AstraZeneca$428
  • Antares Pharma, Inc.$390
  • Indivior Inc.$377
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,764100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,771 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$291,488
Medicare patients
450
Services billed
6,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$141,813
MounjaroTirzepatide87$110,513
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl550$104,337
Xtampza ErOxycodone Myristate89$68,726
FarxigaDapagliflozin Propanediol66$55,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$55,717
LinzessLinaclotide77$54,175
JanuviaSitagliptin Phosphate31$45,532
RybelsusSemaglutide22$43,716
EliquisApixaban46$43,690
XareltoRivaroxaban41$36,618
JardianceEmpagliflozin26$31,543
SuboxoneBuprenorphine Hcl/Naloxone Hcl47$27,036
JanumetSitagliptin Phos/Metformin Hcl26$26,792
TrulicityDulaglutide19$23,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$769$185,529127 claims
Lilly USA, LLCMounjaro, Trulicity$351$133,644106 claims
MerckJanuvia, Janumet, Janumet Xr$182$82,97670 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$283$80,497101 claims
AstraZenecaFarxiga, Symbicort$428$61,28879 claims
AbbVieLinzess, Savella$1,366$59,67789 claims
GSKTrelegy Ellipta$175$55,71765 claims
PfizerEliquis, Prempro, Paxlovid$131$52,49076 claims
Johnson & JohnsonXarelto$31$36,61841 claims
Boehringer IngelheimJardiance$14$31,54326 claims
Indivior Inc.Suboxone$377$27,03647 claims
Otsuka America Pharmaceutical, Inc.Rexulti$163$20,93413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →